Parkinson’s UK invests £2.1 million in Neumora Therapeutics for preclinical testing of new Parkinson’s...
Parkinson’s UK is investing £2.1million to support Neumora Therapeutics to carry out preclinical testing of NMRA-NLRP3, a NLRP3 inhibitor with the potential to reduce inflammation and protect brain cells in Parkinson’s. NLRP3 is a...
Machine learning-powered robot streamlines genetic research process
University of Minnesota Twin Cities researchers have constructed a robot that uses machine learning to fully automate a complicated microinjection process used in genetic research. In their experiments, the researchers were able to use...
Cancer Can Form without Genetic Mutations, Just Epigenetic Changes
The roots of cancer run deep. Indeed, they’re usually assumed to run all the way to the blighted bits of DNA we call oncogenic mutations. But what if they don’t have to run quite...
Curran named Fellow of SAE, ASME
Scott Curran, group leader for Fuel Science and Engine Technologies Research at the Department of Energy’s Oak Ridge National Laboratory, has been named a Fellow of SAE International and the American Society of Mechanical...
Illuminating Darwin’s ‘abominable mystery’— Vast DNA tree of life for plants revealed
The flowering plant tree of life, much like our own family tree, allows us to understand how different species are related to each other. The tree of life is revealed by comparing DNA sequences...
Insilico Targets MTAP Deleted Cancers with AI-Designed Candidate
Michelle Chen, PhD, Insilico Medicine Chief business officer
Insilico Medicine is heading to the clinic with its seventh pipeline candidate discovered and designed using generative artificial intelligence (AI), a treatment for methylthioadenosine phosphorylase (MTAP) deleted...
Insilico Medicine’s AI-designed drug ISM3412 receives FDA IND approval
Clinical stage artificial intelligence (AI)-driven drug discovery company Insilico Medicine ("Insilico") announces that it has received approval from the U.S. Food and Drug Administration (FDA) for its Investigational New Drug (IND) application for ISM3412,...
AI Drug Developer Xaira Therapeutics Launches with $1B+
Marc Tessier-Lavigne, PhD, Xaira Therapeutics founding CEO, and Bing presidential professor, head of laboratory at Stanford University
AI-based drug developer Xaira Therapeutics has been launched with more than $1 billion in capital and a self-described...
Ludwig Lausanne scientists identify and show how to target a key tumor defense against...
April 24, 2024, NEW YORK – A Ludwig Cancer Research study has discovered how a lipid molecule found at high levels within tumors undermines the anti-cancer immune response and compromises a recently approved immunotherapy...
Accelerating Research with Configurable Workflow, AI Assistants and FAIR Data
REGISTER NOW
Broadcast Date: Wednesday, April 24, 2024Time: 8:00 am PDT, 11:00 am EDT, 17:00 CEST
Workflow design and data management are pivotal components of cell and gene therapy research and development. Advances in...
